Jellagen
producing jellyfish-derived Collagen Type Zero, formed a strategic partnership with US-based Royal Biologics in early 2026 to commercialize the material for the North American regenerative-medicine market, covering wound care and tissue-engineering applications.
- Country
- United Kingdom
jellyfish-derived
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen & gelatin | fibers-textiles | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.